Recent News

• 09.16.2025 - Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
• 09.10.2025 - Elutia at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.09.2025 - Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
• 09.04.2025 - Elutia at the Cantor Global Healthcare Conference
• 09.04.2025 - Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
• 08.27.2025 - Elutia to Participate in Upcoming Investor Conferences
• 08.14.2025 - Elutia Q2 2025 Financial Results Call
• 08.14.2025 - Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
• 07.31.2025 - Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
• 07.31.2025 - Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award

Recent Filings

• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.09.2025 - 8-K Current report
• 09.09.2025 - EX-99.1 EX-99.1
• 08.20.2025 - 8-K Current report
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - 8-K Current report